Cancer Research Cell Death Mechanisms and Cancer Therapy  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shinohara, T.
Right arrow Articles by Sone, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shinohara, T.
Right arrow Articles by Sone, S.
[Cancer Research 61, 673-678, January 15, 2001]
© 2001 American Association for Cancer Research


Molecular Biology and Genetics

Nuclear Factor-{kappa}B-dependent Expression of Metastasis Suppressor KAI1/CD82 Gene in Lung Cancer Cell Lines Expressing Mutant p531

Tsutomu Shinohara2, Toyokazu Miki, Naoki Nishimura, Hiroshi Nokihara, Hirofumi Hamada, Naofumi Mukaida and Saburo Sone

Third Department of Internal Medicine, The University of Tokushima School of Medicine, Tokushima 770 [T. S., T. M., N. N., H. N., S. S.]; Department of Molecular Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920 [N. M.]; and Department of Molecular Medicine, Sapporo Medical University, Sapporo 060 [H. H.], Japan

KAI1/CD82 has been shown to be a metastasis suppressor for several human cancers, and a recent study revealed that wild-type tumor suppressor p53 can directly activate KAI1/CD82 gene expression. However, the response of KAI1/CD82 expression in cancer cells to exogenous stimulants has not been investigated. The present study examined whether tumor necrosis factor (TNF), which mediates many of the cellular responses associated with inflammatory reactions or cancer progression, can affect the KAI1/CD82 expression in lung cancer cells and, if so, whether nuclear factor (NF)-{kappa}B, a key molecule in TNF-mediated gene expression, is involved in the mechanism of KAI1/CD82 induction. Our results demonstrated that expression of KAI1/CD82 in PC-14 cells expressing mutant p53 could be augmented by TNF-{alpha}, and that transfer of the gene for a specific inhibitor of NF-{kappa}B, I{kappa}B{alpha}SR (mutant I{kappa}B{alpha}; NF-{kappa}B super-repressor), into PC-14 cells could inhibit this augmentation. The amount of NF-{kappa}B in the nucleus of PC-14/I{kappa}B{alpha}SR cells correlated well with KAI1/CD82 mRNA and protein expression. In addition, I{kappa}B{alpha}SR gene transfer inhibited the spontaneous expression of KAI1/CD82 protein in KAI1/CD82-high-expressing RERF-LC-OK cells, which contain a mutant-type p53. These observations indicate that NF-{kappa}B activation may play a role in the regulation of KAI1/CD82 expression in lung cancer cells independently of wild-type p53, and suggest that KAI1/CD82 expression may be regulated by interaction with the host microenvironment.




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
G. Sethi, B. Sung, and B. B. Aggarwal
Nuclear Factor-{kappa}B Activation: From Bench to Bedside
Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Bao, C. Cao, X. Zhang, F. Jiang, S. V. Nicosia, and W. Bai
Suppression of {beta}-Amyloid Precursor Protein Signaling into the Nucleus by Estrogens Mediated through Complex Formation between the Estrogen Receptor and Fe65
Mol. Cell. Biol., February 15, 2007; 27(4): 1321 - 1333.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. L. Lee, H. S. Lee, J. Jung, S. J. Cho, H.-Y. Chung, W. H. Kim, Y.-W. Jin, C. S. Kim, and S. Y. Nam
Nuclear Factor-{kappa}B Activation Correlates with Better Prognosis and Akt Activation in Human Gastric Cancer
Clin. Cancer Res., April 1, 2005; 11(7): 2518 - 2525.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Huang, Y. Fang, J. Wu, J. M. Dziadyk, X. Zhu, M. Sui, and W. Fan
Regulation of Vinca alkaloid-induced apoptosis by NF-{kappa}B/I{kappa}B pathway in human tumor cells
Mol. Cancer Ther., March 1, 2004; 3(3): 271 - 277.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
Z. Zhang, M. Li, H. Wang, S. Agrawal, and R. Zhang
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy
PNAS, September 30, 2003; 100(20): 11636 - 11641.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Uzawa, K. Ono, H. Suzuki, C. Tanaka, T. Yakushiji, N. Yamamoto, H. Yokoe, and H. Tanzawa
High Prevalence of Decreased Expression of KAI1 Metastasis Suppressor in Human Oral Carcinogenesis
Clin. Cancer Res., March 1, 2002; 8(3): 828 - 835.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y. Huang and W. Fan
Ikappa B Kinase Activation Is Involved in Regulation of Paclitaxel-Induced Apoptosis in Human Tumor Cell Lines
Mol. Pharmacol., January 1, 2002; 61(1): 105 - 113.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.